Infinity Pharmaceuticals’ IPI-549 Patent Portfolio


Jones Day is representing Infinity Pharmaceuticals.

Jones Day represents Infinity Pharmaceuticals, Inc. in the establishment of a global patent portfolio related to IPI-549.

IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

The Jones Day team is led by Michael Bruner (Picture).

Involved fees earner: Michael Bruner – Jones Day;

Law Firms: Jones Day;

Clients: Infinity Pharmaceuticals Inc;

Author: Ambrogio Visconti